PR Newswire Clinical TrialsOriginal article
The Next Chapter of B7-H3: From Systemic Disease to the Brain
ConferenceB7-H3 Allogeneic CAR-TB7-H3 ADCsPositive
AI Analysis
Summary
T-MAXIMUM presented early data for its B7-H3 Allogeneic CAR-T therapy in brain metastases at WCLC 2026, expanding the clinical investigation of B7-H3 targeted approaches from systemic small cell lung cancer to central nervous system involvement.
Clinical Trial Data
Outcome Details
Early data for B7-H3 Allogeneic CAR-T in brain metastases presented at WCLC 2026
Importance:5/10
Sentiment:
0.50
CAR-TB7-H3brain metastasessmall cell lung cancerWCLC 2026allogeneic therapy
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 21, 2026 11:50 AM